Atypical antipsychotic drugs and diabetes

Practical Diabetes International

Volumn 20, Issue 9, 2003, Pages 327-331

  Livingstone, Callum ^a   Rampes, H ^b  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^b WEST LONDON MENTAL HEALTH NHS TRUST   (United Kingdom)

Author keywords

Adverse effects; Atypical antipsychotic drugs; Diabetes; Schizophrenia

Indexed keywords

AMISULPRIDE; ANTIDIABETIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; GLUCOSE; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 4; INSULIN; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZOTEPINE;

AGITATED DEPRESSION; ANXIETY DISORDER; BRAIN INJURY; CORRELATION ANALYSIS; DELIRIUM; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DIET THERAPY; DISEASE EXACERBATION; DRUG ACTIVITY; DRUG CHOICE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE INTAKE; HEART DISEASE; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INSULIN METABOLISM; MENTAL DISEASE; METABOLIC DISORDER; NEGATIVE SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATIENT MONITORING; PSYCHOSIS; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SCREENING; SIDE EFFECT; TREATMENT PLANNING; WEIGHT GAIN;

EID: 0344665738     PISSN: 13578170     EISSN: None     Source Type: Journal    
DOI: 10.1002/pdi.552     Document Type: Review

References (33)

1. National Institute Clinical Excellence, Schizophrenia - Atypical Antipsychotics, Technology Appraisal Guidance No 43, June 2002.
2. Mukherjee S, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Compr Psych 1996; 37: 68-3.
3. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psych 2002; 59: 337-345.
4. Koller E, Schneider B, Bennett K, et al. Clozapine-associated diabetes. Am J Med 2001; 111: 716-723.
5. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain and lipid abnormalities: A five year naturalistic study. Am J Psych 2000; 157: 975-981.
6. Sheitman BB, Bird PM, Binz W, et al. Olanzapine induced elevation of plasma triglyceride levels. Am J Psych 1999; 156: 1471-1472.
7. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: Population based nested case control study. BMJ 2002; 325: 243-245.
8. Henderson DC. Atypical antipsychotic-induced diabetes mellitus. How strong is the evidence? CNS Drugs 2002; 16: 77-89.
9. Procyshyn RM, Pande S, Tse G. New onset diabetes mellitus associated with quetiapine. Can J Psych 2000; 13: 45-50.
10. Meyer JM. A retrospective comparison of weight, lipid and glucose changes between risperidone- and olanzapine-treated inpatients: Metabolic outcomes after one year. J Clin Psych 2002; 63: 425-433.
11. Russell JM, Mackell JA. Bodyweight gain associated with atypical antipsychotics. Epidemiology and therapeutic implications. CNS Drugs 2001; 15: 537-551.
12. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: An analysis of 45 published cases. Ann Clin Psych 2002; 14: 59-64.
13. Koval M, Rames L, Christie S. Diabetic ketoacidosis associated with clozapine treatment. Am J Psych 1994; 151: 1520-1521.
14. Goldstein LE, Sporn L, Brown S, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999; 40: 438-443.
15. Hagg S, Joelsson L, Mjorndal T, et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psych 1998; 59: 294-299.
16. Mir S, Taylor D. Atypical antipsychotics and hyperglycaemia. Int J Psychopharmacol 2001; 16: 63-73.
17. Uvnas-Moberg K, Ahlenius S, Alster P, et al. Effects of selective serotonin and dopamine agonists on plasma levels of glucose, insulin and glucagon in the rat. Neuroendocrinology 1996; 63: 269-274.
18. Yazici KM, Erbas T, Yazici AH. The effect of clozapine on glucose metabolism. J Exp Clin Endocrinol Diab 1998; 106: 475-477.
19. Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psych 1998; 44: 778-783.
20. Melkersson KI, Hulting AL, Brismar KE. Different influences of classical antipsychotic and clozapine on glucose insulin homeostasis in patients with schizophrenia or related psychosis. J Clin Psych 1999; 60: 783-791.
21. Taha C, Klip A. The insulin signaling pathway J Membr Biol 1999; 169: 1-12.
22. Gould GW, Holman GD. The glucose transporter family. Biochem J 1993; 295: 329-341.
23. Livingstone C, Dominiczak AF, Campbell IW, et al. Insulin resistance, hypertension and GLUT4. Clin Sci 1995; 89: 109-116.
24. Moller DE, Flier JS. Insulin resistance - Mechanisms, syndromes and implications. N Engl J Med 1991; 325: 938-948.
25. Ardizzone TD, Bradley RJ, Freeman AM, et al. Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine and structural analogues of clozapine. Brain Res 2001; 923: 82-90.
26. Dwyer DS, Liu Y, Bradley RJ. Dopamine receptor antagonists modulate glucose uptake in rat phaeochromocytoma (PC12) cells. Neurosci Lett 1999; 274: 151-154.
27. Dwyer DS, Pinkofsky HB, Liu Y, et al. Antipsychotic drugs effect glucose uptake and the expression of glucose transporters in PC12 cells. Prog Neuropsychopharmacol Biol Psych 1999; 23: 69-80.
28. Tsai SJ, Huang YH, Huang HJ, et al. Reduced regional [14C]-2-deoxyglucose uptake in response to long term clozapine administration in rats. Neuropsychobiology 2001; 44: 36-40.
29. Avram AM, Patel V, Taylor HC, et al. Euglycaemic clamp study in clozapine-induced diabetic ketoacidosis. Ann Pharmacother 2001; 35: 1381-1387.
30. Melkersson KI, Hulting A-L, Brismar KE. Elevated levels of insulin, leptin and blood lipids in olanzapine-treated patients with schizophrenia or related pschoses. J Clin Psych 2000; 61: 742-749.
31. Henderson DC. Clozapine: Diabetes mellitus, weight gain, and lipid abnormalities. J Clin Psych 2001; 62(Suppl 23): 39-44.
32. Lindenmayer JP, Nathan AM, Smith RC. Hyperglycaemia associated with the use of atypical antipsychotics. J Clin Psych 2001; 174: 180-181.
33. Citrome LL. Efficacy should drive atypical antipsychotic treatment. BMJ 2003; 326: 283.